Silo Pharma (SILO): Bathi resik saben saham sajrone 12 wulan pungkasan

Silo Pharma, Inc. (SILO) is developing psychedelic treatments for PTSD and depression while awaiting regulatory approval to establish pricing. Patent protection for its formulas provides potential for long-term revenue, while physician confidence is based on the safety of microdosing. The TTM fundamental earnings per share trend captures the financial performance, where the value of -3.77 shows the latest figure, helping to assess risks and the speed of business capitalization.
Rincian analitis lan laporan data perusahaan Silo Pharma Inc. (SILO)

Annual net income per share measures the portion of equity attributable to a single security. This metric allows for an assessment of the business's actual profitability by excluding the impact of the total issuance volume. The trend in annual net income per share signals a potential loss of margins. For Silo Pharma, Inc. (SILO), this indicator reflects the efficiency of preclinical program management. Focused management utilizes these metrics to adapt trials to FDA standards.